CHINO HILLS, CALIFORNIA / ACCESS Newswire / May 6, 2025 / SOHM, Inc. (OTC PINK:SHMN), a biotech company at the forefront of precision cellular engineering, announced today the successful development o ...

There is no standard of care for fibrolamellar liver cancer, no targeted therapies. But that may be changing, thanks to ...

A study of human tumor cells implanted in mice from the MacPherson Lab at Fred Hutch describes a new way to screen for the ...

Researchers have shown that activation of the protein YAP, known to help cancer cells survive treatment, behaves very ...

A copy of the presentation materials can be accessed on the “Publications and Posters” section of the Company’s website at https://www.contexttherapeutics.com.

Edgewood Oncology, a clinical-stage biotechnology company focused on delivering BTX-A51 to patients with hematologic ...

NEWTON, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory ...

In the 22Rv1 model, OP-3136 inhibited tumor growth in a dose-dependent manner and, when combined with docetaxel, resulted in enhanced anti-tumor activity. These data indicate OP-3136 may be effective ...

and high Ly6E-expressing cell line-derived xenograft (CDX) and PDX models. ZW327 maintains potential in diverse indications including NSCLC, triple-negative breast cancer, head and neck squamous ...